JP2013505938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505938A5 JP2013505938A5 JP2012531015A JP2012531015A JP2013505938A5 JP 2013505938 A5 JP2013505938 A5 JP 2013505938A5 JP 2012531015 A JP2012531015 A JP 2012531015A JP 2012531015 A JP2012531015 A JP 2012531015A JP 2013505938 A5 JP2013505938 A5 JP 2013505938A5
- Authority
- JP
- Japan
- Prior art keywords
- allotype
- monoclonal antibody
- subject
- phenotype
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000000523 sample Substances 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- 102000054766 genetic haplotypes Human genes 0.000 claims 3
- 239000013641 positive control Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 1
- 239000013642 negative control Substances 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24530509P | 2009-09-24 | 2009-09-24 | |
| US61/245,305 | 2009-09-24 | ||
| PCT/US2010/049924 WO2011038069A1 (en) | 2009-09-24 | 2010-09-23 | Methods, compositions, and kits for reducing anti-antibody responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505938A JP2013505938A (ja) | 2013-02-21 |
| JP2013505938A5 true JP2013505938A5 (enExample) | 2013-10-31 |
Family
ID=43756813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012531015A Pending JP2013505938A (ja) | 2009-09-24 | 2010-09-23 | 抗抗体応答を軽減する方法、組成物およびキット |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US20110070230A1 (enExample) |
| EP (1) | EP2480252A4 (enExample) |
| JP (1) | JP2013505938A (enExample) |
| KR (1) | KR20120093229A (enExample) |
| CN (1) | CN102573895A (enExample) |
| AU (1) | AU2010298264B2 (enExample) |
| CA (1) | CA2775291A1 (enExample) |
| WO (1) | WO2011038069A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160279239A1 (en) * | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US20110070230A1 (en) * | 2009-09-24 | 2011-03-24 | Xbiotech, Inc. | Method and devices for identifying and treating a subject who has developed an anti-antibody response |
| WO2012151199A1 (en) * | 2011-05-02 | 2012-11-08 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| WO2012178173A1 (en) * | 2011-06-24 | 2012-12-27 | Centrose, Llc | Extracellular targeted drug conjugates |
| US20130089496A1 (en) * | 2011-10-07 | 2013-04-11 | Musc Foundation For Research Development | Tumor targeted antibodies and method for using the same |
| US10282875B2 (en) | 2015-12-11 | 2019-05-07 | International Business Machines Corporation | Graph-based analysis for bio-signal event sensing |
| EP3606964A4 (en) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY |
| US10975146B2 (en) | 2018-06-29 | 2021-04-13 | Cedars-Sinai Medical Center | Interleukin-1 inhibition for combination treatment of pancreatic cancer |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105245D0 (en) * | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
| GB9122820D0 (en) * | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| AU5152293A (en) * | 1992-10-08 | 1994-05-09 | Kennedy Institute Of Rheumatology, The | Treatment of autoimmune and inflammatory disorders |
| GB9316989D0 (en) * | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
| US5856095A (en) * | 1995-08-14 | 1999-01-05 | St. Jude Children's Research Hospital | Identification of two novel mutant alleles of human thiopurine S-methyltransferase, and diagnostic uses thereof |
| BRPI9707379C8 (pt) * | 1996-02-09 | 2017-12-12 | Abbott Biotech Ltd | composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. |
| GB9925490D0 (en) * | 1999-10-28 | 1999-12-29 | Univ Cambridge Tech | Binding molecules and treatment and screening methods |
| US20020127625A1 (en) * | 2000-03-31 | 2002-09-12 | Forskarpatent Is Syd Ab | Methods of diagnosing immune related diseases |
| WO2009117409A2 (en) * | 2008-03-18 | 2009-09-24 | Merck & Co., Inc. | A high throughput protein interaction assay |
| US20110070230A1 (en) * | 2009-09-24 | 2011-03-24 | Xbiotech, Inc. | Method and devices for identifying and treating a subject who has developed an anti-antibody response |
-
2010
- 2010-09-23 US US12/888,557 patent/US20110070230A1/en not_active Abandoned
- 2010-09-23 US US12/888,512 patent/US20110071276A1/en not_active Abandoned
- 2010-09-23 CA CA2775291A patent/CA2775291A1/en not_active Abandoned
- 2010-09-23 WO PCT/US2010/049924 patent/WO2011038069A1/en not_active Ceased
- 2010-09-23 JP JP2012531015A patent/JP2013505938A/ja active Pending
- 2010-09-23 US US12/888,534 patent/US20110070229A1/en not_active Abandoned
- 2010-09-23 AU AU2010298264A patent/AU2010298264B2/en active Active
- 2010-09-23 US US12/888,494 patent/US20110071054A1/en not_active Abandoned
- 2010-09-23 EP EP10819428.3A patent/EP2480252A4/en not_active Withdrawn
- 2010-09-23 CN CN2010800468261A patent/CN102573895A/zh active Pending
- 2010-09-23 KR KR1020127010414A patent/KR20120093229A/ko not_active Ceased
-
2011
- 2011-12-02 US US13/310,302 patent/US20120094301A1/en not_active Abandoned
- 2011-12-02 US US13/310,270 patent/US20120094395A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505938A5 (enExample) | ||
| Cho et al. | Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern | |
| Mattoo et al. | Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease | |
| Burnett et al. | Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability | |
| Cho et al. | Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients | |
| KR20220038415A (ko) | 엔테로바이러스 d68에 대한 인간 모노클로날 항체 | |
| CN115768790A (zh) | 针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人单克隆抗体 | |
| JP2020536488A5 (enExample) | ||
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| JP2018065845A (ja) | 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン | |
| Nakagama et al. | Antibody avidity maturation following recovery from infection or the booster vaccination grants breadth of SARS-CoV-2 neutralizing capacity | |
| JP2014524733A5 (enExample) | ||
| JP2021500916A5 (enExample) | ||
| Rouet et al. | Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies | |
| JP6868655B2 (ja) | Ｃｄ６結合パートナーの使用およびそれに基づく方法 | |
| JP2020510409A5 (enExample) | ||
| CN104244979A (zh) | 使用il-17拮抗剂治疗强直性脊柱炎的方法 | |
| Cho et al. | Determinants of VH1-46 cross-reactivity to pemphigus vulgaris autoantigen desmoglein 3 and rotavirus antigen VP6 | |
| Yang et al. | Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouseHG mice through rapid hybridoma screening and high-throughput single-cell V (D) J sequencing | |
| RU2018117651A (ru) | Бактерицидное моноклональное антитело, нацеленное на klebsiella pneumoniae | |
| Niu et al. | Longitudinal analysis of the antibody repertoire of a Zika virus-infected patient revealed dynamic changes in antibody response | |
| RU2017132168A (ru) | Антитела, нацеленные на о-антиген на основе галактана из к.pneumoniae | |
| Chia et al. | Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor | |
| Changrob et al. | Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants | |
| JP2012523221A5 (enExample) |